Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $4.5720 million for the quarter. Parties can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.65 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

ABEO stock traded up $0.21 during trading on Wednesday, hitting $6.04. 534,101 shares of the stock traded hands, compared to its average volume of 1,181,594. Abeona Therapeutics has a one year low of $4.00 and a one year high of $7.54. The stock has a market cap of $343.27 million, a price-to-earnings ratio of 5.86 and a beta of 1.35. The company has a 50 day simple moving average of $4.99 and a 200 day simple moving average of $5.03. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABEO. Tang Capital Management LLC acquired a new stake in Abeona Therapeutics in the 4th quarter valued at about $5,270,000. Geode Capital Management LLC grew its position in shares of Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares during the period. Cable Car Capital LP acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $3,168,000. JPMorgan Chase & Co. grew its position in shares of Abeona Therapeutics by 255.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after buying an additional 597,373 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Abeona Therapeutics during the 4th quarter worth approximately $3,118,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

ABEO has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, March 19th. Stifel Nicolaus set a $17.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, March 17th. Finally, Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $19.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.